Ignite Creation Date:
2025-12-25 @ 4:11 AM
Ignite Modification Date:
2026-02-24 @ 12:25 AM
Study NCT ID:
NCT02289820
Status:
COMPLETED
Last Update Posted:
2018-03-15
First Post:
2014-11-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'information.center@astrazeneca.com', 'phone': '+1-301-398-4010', 'title': 'Judith Falloon, MD, FACP, FIDSA, Senior Director, Clinical Development', 'organization': 'MedImmune LLC'}, 'certainAgreement': {'otherDetails': 'MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'AEs and SAEs were collected from time of signature of informed consent throughout the treatment period and including the follow-up period through the Day 29 visit and day of last subject contact (Day 361 visit), respectively', 'eventGroups': [{'id': 'EG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.', 'otherNumAtRisk': 39, 'otherNumAffected': 2, 'seriousNumAtRisk': 39, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.', 'otherNumAtRisk': 44, 'otherNumAffected': 8, 'seriousNumAtRisk': 44, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.', 'otherNumAtRisk': 39, 'otherNumAffected': 5, 'seriousNumAtRisk': 39, 'seriousNumAffected': 2}, {'id': 'EG003', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.', 'otherNumAtRisk': 40, 'otherNumAffected': 9, 'seriousNumAtRisk': 40, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.', 'otherNumAtRisk': 40, 'otherNumAffected': 11, 'seriousNumAtRisk': 40, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA)+ IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.', 'otherNumAtRisk': 39, 'otherNumAffected': 8, 'seriousNumAtRisk': 39, 'seriousNumAffected': 1}, {'id': 'EG006', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.', 'otherNumAtRisk': 20, 'otherNumAffected': 6, 'seriousNumAtRisk': 20, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Angina pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Coronary artery disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Blepharospasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Iridocyclitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Abdominal pain lower', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Dental caries', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Gastrooesophageal reflux disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Axillary pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Injection site reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Gastroenteritis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Laryngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Pharyngitis streptococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Viral upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Bone contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Humerus fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Post-traumatic pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Wound haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Wrist fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Hyperlipidaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Hypoglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Musculoskeletal chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Neck pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Balance disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Dysuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Urinary hesitation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Prostatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Paranasal sinus discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Productive cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Rhinitis allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Sneezing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Blood blister', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Ecchymosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}], 'seriousEvents': [{'term': 'Cardiac arrest', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Breast cancer female', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Invasive ductal breast carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Rectal adenocarcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants With Solicited Symptoms', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '38', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '35.9', 'groupId': 'OG000'}, {'value': '73.7', 'groupId': 'OG001'}, {'value': '60.0', 'groupId': 'OG002'}, {'value': '60.0', 'groupId': 'OG003'}, {'value': '63.6', 'groupId': 'OG004'}, {'value': '75.0', 'groupId': 'OG005'}, {'value': '68.4', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 1 to Day 7', 'description': 'Solicited symptoms are events that are considered likely to occur post dosing and included the local reaction (pain, tenderness or soreness, redness, and swelling at the site of injection) to investigational product (IP) injection and systemic symptoms (fever greater than or equal to \\[\\>=\\] 100.4°F \\[\\>=38°C\\] by any route, headache, generalized muscle aches, and fatigue or tiredness) that might be related to IP injection. Solicited symptoms were not coded using Medical Dictionary for Regulatory Activities (MedDRA) and summarized regardless of whether or not they are treatment emergent. The percentage of participants with solicited symptoms were recorded during Days 1 (day of dosing) through 7.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'As-treated Population (ATP) included all participants who received any amount of study drug.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '39', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.1', 'groupId': 'OG000'}, {'value': '15.4', 'groupId': 'OG001'}, {'value': '22.5', 'groupId': 'OG002'}, {'value': '30.0', 'groupId': 'OG003'}, {'value': '18.2', 'groupId': 'OG004'}, {'value': '27.5', 'groupId': 'OG005'}, {'value': '20.5', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Day 1 to Day 29', 'description': 'An adverse event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Treatment-emergent were the events between administration of study drug and including the follow-up period through Day 29. The AEs were summarized using the Medical Dictionary for Regulatory Activities version 18.1.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ATP included all participants who received any amount of study drug.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With Treatment-emergent Serious Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '39', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.6', 'groupId': 'OG000'}, {'value': '5.1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2.3', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '2.6', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Day 1 to Day 361', 'description': 'A serious adverse event (SAE) was an AE resulting in any of following reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk), persistent or significant disability/incapacity, congenital anomaly, and a medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ATP included all participants who received any amount of study drug.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With New Onset Chronic Diseases (NOCDs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '39', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.6', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '5.0', 'groupId': 'OG002'}, {'value': '5.0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Day 1 to Day 361', 'description': 'A NOCD was a newly diagnosed medical condition that is of a chronic, ongoing nature. It was observed after receiving study drug and was assessed by investigator as medically significant. All NOCDs were recorded from the time of dosing through the day of the last participant contact (Day 361 visit).', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ATP included all participants who received any amount of study drug.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '39', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '2.5', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Day 1 to Day 361', 'description': 'An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. Treatment emergent AESIs were collected from the time of dosing through the day of the last participant contact (Day 361 visit).', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ATP included all participants who received any amount of study drug.'}, {'type': 'SECONDARY', 'title': 'Geometric Mean Titers (GMTs) of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '38', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'title': 'Baseline (Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '38', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '441.15', 'groupId': 'OG000', 'lowerLimit': '344.99', 'upperLimit': '564.11'}, {'value': '397.52', 'groupId': 'OG001', 'lowerLimit': '279.60', 'upperLimit': '565.17'}, {'value': '401.85', 'groupId': 'OG002', 'lowerLimit': '313.66', 'upperLimit': '514.82'}, {'value': '504.78', 'groupId': 'OG003', 'lowerLimit': '332.66', 'upperLimit': '765.95'}, {'value': '513.53', 'groupId': 'OG004', 'lowerLimit': '414.42', 'upperLimit': '636.36'}, {'value': '365.19', 'groupId': 'OG005', 'lowerLimit': '275.62', 'upperLimit': '483.87'}, {'value': '510.88', 'groupId': 'OG006', 'lowerLimit': '416.00', 'upperLimit': '627.40'}]}]}, {'title': 'Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '37', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '1068.43', 'groupId': 'OG000', 'lowerLimit': '820.93', 'upperLimit': '1390.57'}, {'value': '1233.62', 'groupId': 'OG001', 'lowerLimit': '1010.37', 'upperLimit': '1506.21'}, {'value': '1004.49', 'groupId': 'OG002', 'lowerLimit': '839.19', 'upperLimit': '1202.36'}, {'value': '1217.75', 'groupId': 'OG003', 'lowerLimit': '867.21', 'upperLimit': '1709.98'}, {'value': '464.13', 'groupId': 'OG004', 'lowerLimit': '372.16', 'upperLimit': '578.82'}, {'value': '958.74', 'groupId': 'OG005', 'lowerLimit': '792.78', 'upperLimit': '1159.45'}, {'value': '1370.55', 'groupId': 'OG006', 'lowerLimit': '1115.61', 'upperLimit': '1683.75'}]}]}, {'title': 'Day 61', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '36', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '1168.56', 'groupId': 'OG000', 'lowerLimit': '915.50', 'upperLimit': '1491.57'}, {'value': '1081.64', 'groupId': 'OG003', 'lowerLimit': '750.47', 'upperLimit': '1558.93'}, {'value': '626.09', 'groupId': 'OG004', 'lowerLimit': '509.37', 'upperLimit': '769.57'}, {'value': '816.33', 'groupId': 'OG005', 'lowerLimit': '676.78', 'upperLimit': '984.64'}, {'value': '1151.62', 'groupId': 'OG006', 'lowerLimit': '939.64', 'upperLimit': '1411.41'}]}]}, {'title': 'Day 91', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '37', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '1078.35', 'groupId': 'OG000', 'lowerLimit': '839.60', 'upperLimit': '1385.00'}, {'value': '967.42', 'groupId': 'OG003', 'lowerLimit': '665.58', 'upperLimit': '1406.14'}, {'value': '579.56', 'groupId': 'OG004', 'lowerLimit': '463.07', 'upperLimit': '725.34'}, {'value': '765.63', 'groupId': 'OG005', 'lowerLimit': '642.61', 'upperLimit': '912.20'}, {'value': '1072.70', 'groupId': 'OG006', 'lowerLimit': '854.84', 'upperLimit': '1346.08'}]}]}, {'title': 'Day 181', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '36', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '866.23', 'groupId': 'OG000', 'lowerLimit': '673.55', 'upperLimit': '1114.04'}, {'value': '763.51', 'groupId': 'OG003', 'lowerLimit': '514.29', 'upperLimit': '1133.49'}, {'value': '548.46', 'groupId': 'OG004', 'lowerLimit': '439.44', 'upperLimit': '684.53'}, {'value': '631.44', 'groupId': 'OG005', 'lowerLimit': '511.84', 'upperLimit': '778.99'}, {'value': '900.59', 'groupId': 'OG006', 'lowerLimit': '716.04', 'upperLimit': '1132.70'}]}]}, {'title': 'Day 271', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}, {'value': '39', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '796.48', 'groupId': 'OG000', 'lowerLimit': '607.83', 'upperLimit': '1043.70'}, {'value': '579.19', 'groupId': 'OG003', 'lowerLimit': '329.21', 'upperLimit': '1018.98'}, {'value': '546.80', 'groupId': 'OG004', 'lowerLimit': '435.46', 'upperLimit': '686.62'}, {'value': '565.08', 'groupId': 'OG005', 'lowerLimit': '460.42', 'upperLimit': '693.53'}, {'value': '690.36', 'groupId': 'OG006', 'lowerLimit': '552.52', 'upperLimit': '862.59'}]}]}, {'title': 'Day 361', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}, {'value': '34', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}, {'value': '35', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '746.01', 'groupId': 'OG000', 'lowerLimit': '594.45', 'upperLimit': '936.22'}, {'value': '814.32', 'groupId': 'OG003', 'lowerLimit': '515.32', 'upperLimit': '1286.80'}, {'value': '573.22', 'groupId': 'OG004', 'lowerLimit': '458.58', 'upperLimit': '716.51'}, {'value': '533.55', 'groupId': 'OG005', 'lowerLimit': '426.01', 'upperLimit': '668.23'}, {'value': '692.93', 'groupId': 'OG006', 'lowerLimit': '554.05', 'upperLimit': '866.62'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Baseline (Day 1), Day 29, 61, 91, 181, 271, and 361', 'description': 'GMTs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay at Baseline and the results through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A. Immunogenicity population is defined as all participants in ATP who had no protocol deviation judged to have the potential to interfere with generation or interpretation of an immune response.', 'unitOfMeasure': 'Titers', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Immunogenicity population'}, {'type': 'SECONDARY', 'title': 'Geometric Mean Fold Rises (GMFRs) of Serum Antibodies Against RSV by RSV A Microneutralization Assay', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '38', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'title': 'Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '37', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '2.42', 'groupId': 'OG000', 'lowerLimit': '1.96', 'upperLimit': '2.99'}, {'value': '3.26', 'groupId': 'OG001', 'lowerLimit': '2.29', 'upperLimit': '4.63'}, {'value': '2.50', 'groupId': 'OG002', 'lowerLimit': '2.11', 'upperLimit': '2.97'}, {'value': '2.41', 'groupId': 'OG003', 'lowerLimit': '1.82', 'upperLimit': '3.20'}, {'value': '0.92', 'groupId': 'OG004', 'lowerLimit': '0.86', 'upperLimit': '0.97'}, {'value': '2.63', 'groupId': 'OG005', 'lowerLimit': '2.17', 'upperLimit': '3.18'}, {'value': '2.64', 'groupId': 'OG006', 'lowerLimit': '2.12', 'upperLimit': '3.30'}]}]}, {'title': 'Day 61', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '36', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '2.65', 'groupId': 'OG000', 'lowerLimit': '2.21', 'upperLimit': '3.17'}, {'value': '2.14', 'groupId': 'OG003', 'lowerLimit': '1.60', 'upperLimit': '2.87'}, {'value': '1.24', 'groupId': 'OG004', 'lowerLimit': '1.08', 'upperLimit': '1.42'}, {'value': '2.24', 'groupId': 'OG005', 'lowerLimit': '1.81', 'upperLimit': '2.76'}, {'value': '2.20', 'groupId': 'OG006', 'lowerLimit': '1.79', 'upperLimit': '2.70'}]}]}, {'title': 'Day 91', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '37', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '2.44', 'groupId': 'OG000', 'lowerLimit': '2.05', 'upperLimit': '2.92'}, {'value': '1.92', 'groupId': 'OG003', 'lowerLimit': '1.43', 'upperLimit': '2.56'}, {'value': '1.14', 'groupId': 'OG004', 'lowerLimit': '1.04', 'upperLimit': '1.25'}, {'value': '2.10', 'groupId': 'OG005', 'lowerLimit': '1.70', 'upperLimit': '2.59'}, {'value': '2.07', 'groupId': 'OG006', 'lowerLimit': '1.65', 'upperLimit': '2.59'}]}]}, {'title': 'Day 181', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '36', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '1.99', 'groupId': 'OG000', 'lowerLimit': '1.72', 'upperLimit': '2.30'}, {'value': '1.51', 'groupId': 'OG003', 'lowerLimit': '1.20', 'upperLimit': '1.91'}, {'value': '1.15', 'groupId': 'OG004', 'lowerLimit': '1.02', 'upperLimit': '1.30'}, {'value': '1.73', 'groupId': 'OG005', 'lowerLimit': '1.44', 'upperLimit': '2.08'}, {'value': '1.68', 'groupId': 'OG006', 'lowerLimit': '1.37', 'upperLimit': '2.06'}]}]}, {'title': 'Day 271', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}, {'value': '39', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '1.83', 'groupId': 'OG000', 'lowerLimit': '1.57', 'upperLimit': '2.14'}, {'value': '1.08', 'groupId': 'OG003', 'lowerLimit': '0.64', 'upperLimit': '1.81'}, {'value': '1.11', 'groupId': 'OG004', 'lowerLimit': '0.96', 'upperLimit': '1.27'}, {'value': '1.56', 'groupId': 'OG005', 'lowerLimit': '1.32', 'upperLimit': '1.86'}, {'value': '1.42', 'groupId': 'OG006', 'lowerLimit': '1.18', 'upperLimit': '1.70'}]}]}, {'title': 'Day 361', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}, {'value': '34', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}, {'value': '35', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '1.71', 'groupId': 'OG000', 'lowerLimit': '1.50', 'upperLimit': '1.96'}, {'value': '1.47', 'groupId': 'OG003', 'lowerLimit': '1.12', 'upperLimit': '1.93'}, {'value': '1.15', 'groupId': 'OG004', 'lowerLimit': '1.00', 'upperLimit': '1.31'}, {'value': '1.50', 'groupId': 'OG005', 'lowerLimit': '1.27', 'upperLimit': '1.77'}, {'value': '1.34', 'groupId': 'OG006', 'lowerLimit': '1.14', 'upperLimit': '1.56'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 29, 61, 91, 181, 271, and 361', 'description': 'GMFRs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay from Baseline line through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.', 'unitOfMeasure': 'Fold rise', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "Immunogenicity Population. Here, 'n' is number of participants analyzed for this outcome measure at given time points."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Post-dose Seroresponse to RSV by RSV A Microneutralization Assay', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '38', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '41.0', 'groupId': 'OG000', 'lowerLimit': '25.57', 'upperLimit': '57.90'}, {'value': '42.1', 'groupId': 'OG001', 'lowerLimit': '26.31', 'upperLimit': '59.18'}, {'value': '42.5', 'groupId': 'OG002', 'lowerLimit': '27.04', 'upperLimit': '59.11'}, {'value': '30.0', 'groupId': 'OG003', 'lowerLimit': '11.89', 'upperLimit': '54.28'}, {'value': '0', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '8.22'}, {'value': '35.0', 'groupId': 'OG005', 'lowerLimit': '20.63', 'upperLimit': '51.68'}, {'value': '40.5', 'groupId': 'OG006', 'lowerLimit': '24.75', 'upperLimit': '57.90'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 29', 'description': 'Seroresponse defined as a greater than or equal to (\\>=) 3-fold rise in titer from baseline. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Immunogenicity population.'}, {'type': 'SECONDARY', 'title': 'Geometric Mean Concentrations of Serum Antibodies Against RSV by Anti F Immunoglobulin G (IgG) Assay', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '38', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'title': 'Baseline (Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '38', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '99.63', 'groupId': 'OG000', 'lowerLimit': '74.22', 'upperLimit': '133.73'}, {'value': '95.29', 'groupId': 'OG001', 'lowerLimit': '62.83', 'upperLimit': '144.54'}, {'value': '101.51', 'groupId': 'OG002', 'lowerLimit': '75.45', 'upperLimit': '136.58'}, {'value': '67.93', 'groupId': 'OG003', 'lowerLimit': '30.62', 'upperLimit': '150.71'}, {'value': '92.34', 'groupId': 'OG004', 'lowerLimit': '76.64', 'upperLimit': '111.25'}, {'value': '70.18', 'groupId': 'OG005', 'lowerLimit': '55.27', 'upperLimit': '89.11'}, {'value': '82.13', 'groupId': 'OG006', 'lowerLimit': '64.16', 'upperLimit': '105.14'}]}]}, {'title': 'Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '37', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '1328.36', 'groupId': 'OG000', 'lowerLimit': '958.76', 'upperLimit': '1840.45'}, {'value': '1433.98', 'groupId': 'OG001', 'lowerLimit': '1053.24', 'upperLimit': '1952.34'}, {'value': '1047.68', 'groupId': 'OG002', 'lowerLimit': '810.79', 'upperLimit': '1353.79'}, {'value': '1003.07', 'groupId': 'OG003', 'lowerLimit': '566.77', 'upperLimit': '1775.23'}, {'value': '92.94', 'groupId': 'OG004', 'lowerLimit': '76.81', 'upperLimit': '112.46'}, {'value': '1066.90', 'groupId': 'OG005', 'lowerLimit': '836.10', 'upperLimit': '1361.42'}, {'value': '1474.47', 'groupId': 'OG006', 'lowerLimit': '1110.41', 'upperLimit': '1957.90'}]}]}, {'title': 'Day 61', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '37', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '1050.29', 'groupId': 'OG000', 'lowerLimit': '774.32', 'upperLimit': '1424.61'}, {'value': '852.27', 'groupId': 'OG003', 'lowerLimit': '491.53', 'upperLimit': '1477.76'}, {'value': '104.00', 'groupId': 'OG004', 'lowerLimit': '80.54', 'upperLimit': '134.30'}, {'value': '850.91', 'groupId': 'OG005', 'lowerLimit': '661.84', 'upperLimit': '1093.99'}, {'value': '1097.04', 'groupId': 'OG006', 'lowerLimit': '816.40', 'upperLimit': '1474.15'}]}]}, {'title': 'Day 91', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '37', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '817.05', 'groupId': 'OG000', 'lowerLimit': '603.67', 'upperLimit': '1105.86'}, {'value': '662.15', 'groupId': 'OG003', 'lowerLimit': '375.50', 'upperLimit': '1167.62'}, {'value': '95.29', 'groupId': 'OG004', 'lowerLimit': '77.73', 'upperLimit': '116.82'}, {'value': '705.96', 'groupId': 'OG005', 'lowerLimit': '547.07', 'upperLimit': '910.99'}, {'value': '845.04', 'groupId': 'OG006', 'lowerLimit': '636.42', 'upperLimit': '1122.04'}]}]}, {'title': 'Day 181', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '36', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '501.47', 'groupId': 'OG000', 'lowerLimit': '368.62', 'upperLimit': '682.20'}, {'value': '403.58', 'groupId': 'OG003', 'lowerLimit': '226.56', 'upperLimit': '718.92'}, {'value': '91.54', 'groupId': 'OG004', 'lowerLimit': '74.62', 'upperLimit': '112.29'}, {'value': '466.81', 'groupId': 'OG005', 'lowerLimit': '363.97', 'upperLimit': '598.71'}, {'value': '531.43', 'groupId': 'OG006', 'lowerLimit': '398.10', 'upperLimit': '709.41'}]}]}, {'title': 'Day 271', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}, {'value': '39', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '389.94', 'groupId': 'OG000', 'lowerLimit': '286.92', 'upperLimit': '529.96'}, {'value': '341.99', 'groupId': 'OG003', 'lowerLimit': '160.13', 'upperLimit': '730.40'}, {'value': '92.70', 'groupId': 'OG004', 'lowerLimit': '75.46', 'upperLimit': '113.88'}, {'value': '356.11', 'groupId': 'OG005', 'lowerLimit': '276.99', 'upperLimit': '457.84'}, {'value': '423.30', 'groupId': 'OG006', 'lowerLimit': '316.79', 'upperLimit': '565.61'}]}]}, {'title': 'Day 361', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}, {'value': '34', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}, {'value': '35', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '343.64', 'groupId': 'OG000', 'lowerLimit': '255.99', 'upperLimit': '461.32'}, {'value': '284.56', 'groupId': 'OG003', 'lowerLimit': '140.69', 'upperLimit': '575.55'}, {'value': '94.10', 'groupId': 'OG004', 'lowerLimit': '74.03', 'upperLimit': '119.61'}, {'value': '305.10', 'groupId': 'OG005', 'lowerLimit': '235.90', 'upperLimit': '394.60'}, {'value': '354.13', 'groupId': 'OG006', 'lowerLimit': '268.29', 'upperLimit': '467.43'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Baseline (Day 1), Day 29, 61, 91, 181, 271, and 361', 'description': 'Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.', 'unitOfMeasure': 'F Ab Unit/mL', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "Immunogenicity Population. Here, 'n' is number of participants analyzed for this outcome measure at given time points."}, {'type': 'SECONDARY', 'title': 'GMFRs of Serum Antibodies Against RSV by Anti F IgG Assay', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '38', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'title': 'Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '37', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '13.33', 'groupId': 'OG000', 'lowerLimit': '9.39', 'upperLimit': '18.93'}, {'value': '15.15', 'groupId': 'OG001', 'lowerLimit': '10.18', 'upperLimit': '22.55'}, {'value': '10.32', 'groupId': 'OG002', 'lowerLimit': '7.87', 'upperLimit': '13.54'}, {'value': '14.77', 'groupId': 'OG003', 'lowerLimit': '7.63', 'upperLimit': '28.59'}, {'value': '0.99', 'groupId': 'OG004', 'lowerLimit': '0.96', 'upperLimit': '1.02'}, {'value': '15.20', 'groupId': 'OG005', 'lowerLimit': '11.29', 'upperLimit': '20.47'}, {'value': '17.95', 'groupId': 'OG006', 'lowerLimit': '14.06', 'upperLimit': '22.91'}]}]}, {'title': 'Day 61', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '37', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '10.54', 'groupId': 'OG000', 'lowerLimit': '7.73', 'upperLimit': '14.37'}, {'value': '12.55', 'groupId': 'OG003', 'lowerLimit': '6.55', 'upperLimit': '24.04'}, {'value': '1.09', 'groupId': 'OG004', 'lowerLimit': '0.91', 'upperLimit': '1.32'}, {'value': '12.13', 'groupId': 'OG005', 'lowerLimit': '9.20', 'upperLimit': '15.98'}, {'value': '13.35', 'groupId': 'OG006', 'lowerLimit': '10.51', 'upperLimit': '16.96'}]}]}, {'title': 'Day 91', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '37', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '8.20', 'groupId': 'OG000', 'lowerLimit': '6.09', 'upperLimit': '11.05'}, {'value': '9.75', 'groupId': 'OG003', 'lowerLimit': '5.37', 'upperLimit': '17.70'}, {'value': '1.00', 'groupId': 'OG004', 'lowerLimit': '0.95', 'upperLimit': '1.05'}, {'value': '10.06', 'groupId': 'OG005', 'lowerLimit': '7.74', 'upperLimit': '13.07'}, {'value': '10.28', 'groupId': 'OG006', 'lowerLimit': '8.18', 'upperLimit': '12.94'}]}]}, {'title': 'Day 181', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '36', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '5.03', 'groupId': 'OG000', 'lowerLimit': '3.89', 'upperLimit': '6.50'}, {'value': '5.94', 'groupId': 'OG003', 'lowerLimit': '3.58', 'upperLimit': '9.85'}, {'value': '0.97', 'groupId': 'OG004', 'lowerLimit': '0.92', 'upperLimit': '1.02'}, {'value': '6.65', 'groupId': 'OG005', 'lowerLimit': '5.23', 'upperLimit': '8.47'}, {'value': '6.23', 'groupId': 'OG006', 'lowerLimit': '5.01', 'upperLimit': '7.74'}]}]}, {'title': 'Day 271', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}, {'value': '39', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '3.91', 'groupId': 'OG000', 'lowerLimit': '3.05', 'upperLimit': '5.02'}, {'value': '4.92', 'groupId': 'OG003', 'lowerLimit': '3.11', 'upperLimit': '7.77'}, {'value': '0.96', 'groupId': 'OG004', 'lowerLimit': '0.91', 'upperLimit': '1.01'}, {'value': '5.14', 'groupId': 'OG005', 'lowerLimit': '4.09', 'upperLimit': '6.44'}, {'value': '4.75', 'groupId': 'OG006', 'lowerLimit': '3.76', 'upperLimit': '5.99'}]}]}, {'title': 'Day 361', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}, {'value': '34', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}, {'value': '35', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '3.45', 'groupId': 'OG000', 'lowerLimit': '2.74', 'upperLimit': '4.33'}, {'value': '4.22', 'groupId': 'OG003', 'lowerLimit': '2.61', 'upperLimit': '6.80'}, {'value': '0.96', 'groupId': 'OG004', 'lowerLimit': '0.91', 'upperLimit': '1.02'}, {'value': '4.47', 'groupId': 'OG005', 'lowerLimit': '3.55', 'upperLimit': '5.65'}, {'value': '4.07', 'groupId': 'OG006', 'lowerLimit': '3.29', 'upperLimit': '5.03'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 29, 61, 91, 181, 271, and 361', 'description': 'The Anti F IgG antibodies were derived from the RSV-specific 4-plex MSD assay developed on the Meso Scale discovery platform. Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.', 'unitOfMeasure': 'Fold rise', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "Immunogenicity Population. Here, 'n' is number of participants analyzed for this outcome measure at given time points."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Post-dose Seroresponse to RSV by Anti-F IgG Assay', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '38', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '94.9', 'groupId': 'OG000', 'lowerLimit': '82.68', 'upperLimit': '99.37'}, {'value': '89.5', 'groupId': 'OG001', 'lowerLimit': '75.20', 'upperLimit': '97.06'}, {'value': '90.0', 'groupId': 'OG002', 'lowerLimit': '76.34', 'upperLimit': '97.21'}, {'value': '85.0', 'groupId': 'OG003', 'lowerLimit': '62.11', 'upperLimit': '96.79'}, {'value': '0', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '8.22'}, {'value': '97.5', 'groupId': 'OG005', 'lowerLimit': '86.84', 'upperLimit': '99.94'}, {'value': '97.3', 'groupId': 'OG006', 'lowerLimit': '85.84', 'upperLimit': '99.93'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 29', 'description': 'Seroresponse defined as a greater than or equal to (\\>=) 3-fold rise from baseline. Humoral immunity against RSV was assessed by an Anti-F IgG assay derived from the RSV-specific 4-plex MSD assay.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Immunogenicity population.'}, {'type': 'SECONDARY', 'title': 'Ratios of GMTs and GMFRs of Hemagglutination Inhibition (HAI) Antibodies', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '40', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'title': 'GMT: H1N1', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.19', 'groupId': 'OG001', 'lowerLimit': '0.71', 'upperLimit': '1.99'}, {'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.01', 'groupId': 'OG003', 'lowerLimit': '0.63', 'upperLimit': '1.61'}]}]}, {'title': 'GMT: H3N2', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.53', 'groupId': 'OG001', 'lowerLimit': '1.03', 'upperLimit': '2.28'}, {'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0.78', 'groupId': 'OG003', 'lowerLimit': '0.53', 'upperLimit': '1.15'}]}]}, {'title': 'GMT: B/Yamagata', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.38', 'groupId': 'OG001', 'lowerLimit': '0.81', 'upperLimit': '2.36'}, {'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.49', 'groupId': 'OG003', 'lowerLimit': '0.91', 'upperLimit': '2.46'}]}]}, {'title': 'GMFR: H1N1', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.13', 'groupId': 'OG001', 'lowerLimit': '0.68', 'upperLimit': '1.87'}, {'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0.97', 'groupId': 'OG003', 'lowerLimit': '0.54', 'upperLimit': '1.75'}]}]}, {'title': 'GMFR: H3N2', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.53', 'groupId': 'OG001', 'lowerLimit': '0.86', 'upperLimit': '2.72'}, {'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.28', 'groupId': 'OG003', 'lowerLimit': '0.69', 'upperLimit': '2.38'}]}]}, {'title': 'GMFR: B/Yamagata', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.09', 'groupId': 'OG001', 'lowerLimit': '0.76', 'upperLimit': '1.55'}, {'value': 'NA', 'comment': 'Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.00', 'groupId': 'OG003', 'lowerLimit': '0.71', 'upperLimit': '1.40'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 29', 'description': 'The ratio of post-dose HAI antibody GMTs and GMFRs in the IIV group and the MEDI7510 plus IIV group was provided by strain and by cohort for Cohorts 2 and 3 to check the effect of MEDI7510 on IIV when administered together. Humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed on Day 29 by each strain (H1N1, H3N2, B/Yamagata).', 'unitOfMeasure': 'Ratio', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Immunogenicity Population.'}, {'type': 'SECONDARY', 'title': 'Geometric Mean Counts of Cellular Immune Response Against RSV by Respiratory Syncytial Virus Fusion Protein (RSV F) Interferon Gamma (IFNγ) Enzyme-linked Immunosorbent Spot (ELISPOT) Assay', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '34', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '39', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '38', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'title': 'Baseline (Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '34', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '36', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '36', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '66.06', 'groupId': 'OG000', 'lowerLimit': '53.40', 'upperLimit': '81.72'}, {'value': '47.21', 'groupId': 'OG001', 'lowerLimit': '39.96', 'upperLimit': '55.77'}, {'value': '50.89', 'groupId': 'OG002', 'lowerLimit': '42.19', 'upperLimit': '61.38'}, {'value': '42.24', 'groupId': 'OG003', 'lowerLimit': '33.84', 'upperLimit': '52.73'}, {'value': '58.53', 'groupId': 'OG004', 'lowerLimit': '47.10', 'upperLimit': '72.74'}, {'value': '45.71', 'groupId': 'OG005', 'lowerLimit': '38.90', 'upperLimit': '53.71'}, {'value': '62.63', 'groupId': 'OG006', 'lowerLimit': '49.89', 'upperLimit': '78.61'}]}]}, {'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}, {'value': '35', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '36', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '436.72', 'groupId': 'OG000', 'lowerLimit': '333.87', 'upperLimit': '571.25'}, {'value': '341.02', 'groupId': 'OG001', 'lowerLimit': '222.54', 'upperLimit': '522.58'}, {'value': '430.33', 'groupId': 'OG002', 'lowerLimit': '308.22', 'upperLimit': '600.83'}, {'value': '379.28', 'groupId': 'OG003', 'lowerLimit': '225.90', 'upperLimit': '636.80'}, {'value': '54.30', 'groupId': 'OG004', 'lowerLimit': '43.86', 'upperLimit': '67.24'}, {'value': '376.43', 'groupId': 'OG005', 'lowerLimit': '273.42', 'upperLimit': '518.25'}, {'value': '618.15', 'groupId': 'OG006', 'lowerLimit': '463.46', 'upperLimit': '824.48'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Baseline (Day 1) and Day 8', 'description': 'The Geometric Mean Counts assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.', 'unitOfMeasure': 'Spot forming counts per 10^6 PBMCs', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "Immunogenicity Population. Here, 'n' is number of participants analyzed for this outcome measure at given time points."}, {'type': 'SECONDARY', 'title': 'GMFRs of Cellular Immune Response Against RSV by RSV F IFNγ ELISPOT Assay', 'denoms': [{'units': 'Participants', 'counts': [{'value': '34', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}, {'value': '32', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '35', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.45', 'groupId': 'OG000', 'lowerLimit': '4.88', 'upperLimit': '8.52'}, {'value': '6.77', 'groupId': 'OG001', 'lowerLimit': '4.13', 'upperLimit': '11.09'}, {'value': '8.67', 'groupId': 'OG002', 'lowerLimit': '6.38', 'upperLimit': '11.78'}, {'value': '8.87', 'groupId': 'OG003', 'lowerLimit': '4.99', 'upperLimit': '15.77'}, {'value': '0.89', 'groupId': 'OG004', 'lowerLimit': '0.76', 'upperLimit': '1.04'}, {'value': '8.23', 'groupId': 'OG005', 'lowerLimit': '5.92', 'upperLimit': '11.46'}, {'value': '10.48', 'groupId': 'OG006', 'lowerLimit': '7.82', 'upperLimit': '14.03'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 8', 'description': 'The GMFRs assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples', 'unitOfMeasure': 'Fold rise', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Immunogenicity Population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Post-dose Cell-mediated Immune Response to RSV F by RSV F Peptide Pool IFNγ ELISPOT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '34', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}, {'value': '32', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '35', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'OG001', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG003', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'OG004', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'OG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'OG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '76.5', 'groupId': 'OG000', 'lowerLimit': '58.83', 'upperLimit': '89.25'}, {'value': '80.8', 'groupId': 'OG001', 'lowerLimit': '60.65', 'upperLimit': '93.45'}, {'value': '90.0', 'groupId': 'OG002', 'lowerLimit': '73.47', 'upperLimit': '97.89'}, {'value': '78.9', 'groupId': 'OG003', 'lowerLimit': '54.43', 'upperLimit': '93.95'}, {'value': '0.00', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '10.89'}, {'value': '82.5', 'groupId': 'OG005', 'lowerLimit': '67.22', 'upperLimit': '92.66'}, {'value': '97.1', 'groupId': 'OG006', 'lowerLimit': '85.08', 'upperLimit': '99.93'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 8', 'description': 'Seroresponse defined as a greater than or equal to (\\>=) 3-fold rise from baseline. The Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Immunogenicity Population.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'FG001', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'FG002', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'FG003', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'FG004', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'FG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'FG006', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA)+ IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '39'}, {'groupId': 'FG001', 'numSubjects': '20'}, {'groupId': 'FG002', 'numSubjects': '44'}, {'groupId': 'FG003', 'numSubjects': '39'}, {'groupId': 'FG004', 'numSubjects': '40'}, {'groupId': 'FG005', 'numSubjects': '40'}, {'groupId': 'FG006', 'numSubjects': '39'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '37'}, {'groupId': 'FG001', 'numSubjects': '18'}, {'groupId': 'FG002', 'numSubjects': '38'}, {'groupId': 'FG003', 'numSubjects': '37'}, {'groupId': 'FG004', 'numSubjects': '40'}, {'groupId': 'FG005', 'numSubjects': '39'}, {'groupId': 'FG006', 'numSubjects': '37'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '6'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '2'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '1'}]}, {'type': 'withdrawal of consent', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'A total of 363 participants were screened. Of these, 264 participants were enrolled.', 'preAssignmentDetails': 'A total of 264 participants were enrolled in the study. Of the 264 randomized participants, 3 participants did not receive the study drug. 261 participants were included in the As-treated Population.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'BG000'}, {'value': '44', 'groupId': 'BG001'}, {'value': '39', 'groupId': 'BG002'}, {'value': '40', 'groupId': 'BG003'}, {'value': '40', 'groupId': 'BG004'}, {'value': '39', 'groupId': 'BG005'}, {'value': '20', 'groupId': 'BG006'}, {'value': '261', 'groupId': 'BG007'}]}], 'groups': [{'id': 'BG000', 'title': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.'}, {'id': 'BG001', 'title': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.'}, {'id': 'BG002', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'BG003', 'title': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'BG004', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.'}, {'id': 'BG005', 'title': 'MEDI7510 (120 mcg sF + 5 mcg GLA)+ IIV, Cohort 3', 'description': 'Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.'}, {'id': 'BG006', 'title': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.'}, {'id': 'BG007', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '70.5', 'spread': '6.9', 'groupId': 'BG000'}, {'value': '69.6', 'spread': '7.0', 'groupId': 'BG001'}, {'value': '69.3', 'spread': '5.2', 'groupId': 'BG002'}, {'value': '67.9', 'spread': '5.8', 'groupId': 'BG003'}, {'value': '70.1', 'spread': '5.9', 'groupId': 'BG004'}, {'value': '70.2', 'spread': '6.8', 'groupId': 'BG005'}, {'value': '68.9', 'spread': '6.5', 'groupId': 'BG006'}, {'value': '69.5', 'spread': '6.3', 'groupId': 'BG007'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '21', 'groupId': 'BG000'}, {'value': '25', 'groupId': 'BG001'}, {'value': '27', 'groupId': 'BG002'}, {'value': '19', 'groupId': 'BG003'}, {'value': '18', 'groupId': 'BG004'}, {'value': '19', 'groupId': 'BG005'}, {'value': '13', 'groupId': 'BG006'}, {'value': '142', 'groupId': 'BG007'}]}, {'title': 'Male', 'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '19', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}, {'value': '21', 'groupId': 'BG003'}, {'value': '22', 'groupId': 'BG004'}, {'value': '20', 'groupId': 'BG005'}, {'value': '7', 'groupId': 'BG006'}, {'value': '119', 'groupId': 'BG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 363}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-01-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-02', 'completionDateStruct': {'date': '2016-02-24', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-02-16', 'studyFirstSubmitDate': '2014-11-10', 'resultsFirstSubmitDate': '2017-01-30', 'studyFirstSubmitQcDate': '2014-11-10', 'lastUpdatePostDateStruct': {'date': '2018-03-15', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2017-08-07', 'studyFirstPostDateStruct': {'date': '2014-11-13', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2018-02-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-02-24', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants With Solicited Symptoms', 'timeFrame': 'Day 1 to Day 7', 'description': 'Solicited symptoms are events that are considered likely to occur post dosing and included the local reaction (pain, tenderness or soreness, redness, and swelling at the site of injection) to investigational product (IP) injection and systemic symptoms (fever greater than or equal to \\[\\>=\\] 100.4°F \\[\\>=38°C\\] by any route, headache, generalized muscle aches, and fatigue or tiredness) that might be related to IP injection. Solicited symptoms were not coded using Medical Dictionary for Regulatory Activities (MedDRA) and summarized regardless of whether or not they are treatment emergent. The percentage of participants with solicited symptoms were recorded during Days 1 (day of dosing) through 7.'}, {'measure': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'From Day 1 to Day 29', 'description': 'An adverse event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Treatment-emergent were the events between administration of study drug and including the follow-up period through Day 29. The AEs were summarized using the Medical Dictionary for Regulatory Activities version 18.1.'}, {'measure': 'Percentage of Participants With Treatment-emergent Serious Adverse Events', 'timeFrame': 'From Day 1 to Day 361', 'description': 'A serious adverse event (SAE) was an AE resulting in any of following reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk), persistent or significant disability/incapacity, congenital anomaly, and a medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above.'}, {'measure': 'Percentage of Participants With New Onset Chronic Diseases (NOCDs)', 'timeFrame': 'From Day 1 to Day 361', 'description': 'A NOCD was a newly diagnosed medical condition that is of a chronic, ongoing nature. It was observed after receiving study drug and was assessed by investigator as medically significant. All NOCDs were recorded from the time of dosing through the day of the last participant contact (Day 361 visit).'}, {'measure': 'Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)', 'timeFrame': 'From Day 1 to Day 361', 'description': 'An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. Treatment emergent AESIs were collected from the time of dosing through the day of the last participant contact (Day 361 visit).'}], 'secondaryOutcomes': [{'measure': 'Geometric Mean Titers (GMTs) of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay', 'timeFrame': 'Baseline (Day 1), Day 29, 61, 91, 181, 271, and 361', 'description': 'GMTs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay at Baseline and the results through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A. Immunogenicity population is defined as all participants in ATP who had no protocol deviation judged to have the potential to interfere with generation or interpretation of an immune response.'}, {'measure': 'Geometric Mean Fold Rises (GMFRs) of Serum Antibodies Against RSV by RSV A Microneutralization Assay', 'timeFrame': 'Day 29, 61, 91, 181, 271, and 361', 'description': 'GMFRs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay from Baseline line through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.'}, {'measure': 'Percentage of Participants With Post-dose Seroresponse to RSV by RSV A Microneutralization Assay', 'timeFrame': 'Day 29', 'description': 'Seroresponse defined as a greater than or equal to (\\>=) 3-fold rise in titer from baseline. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.'}, {'measure': 'Geometric Mean Concentrations of Serum Antibodies Against RSV by Anti F Immunoglobulin G (IgG) Assay', 'timeFrame': 'Baseline (Day 1), Day 29, 61, 91, 181, 271, and 361', 'description': 'Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.'}, {'measure': 'GMFRs of Serum Antibodies Against RSV by Anti F IgG Assay', 'timeFrame': 'Day 29, 61, 91, 181, 271, and 361', 'description': 'The Anti F IgG antibodies were derived from the RSV-specific 4-plex MSD assay developed on the Meso Scale discovery platform. Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.'}, {'measure': 'Percentage of Participants With Post-dose Seroresponse to RSV by Anti-F IgG Assay', 'timeFrame': 'Day 29', 'description': 'Seroresponse defined as a greater than or equal to (\\>=) 3-fold rise from baseline. Humoral immunity against RSV was assessed by an Anti-F IgG assay derived from the RSV-specific 4-plex MSD assay.'}, {'measure': 'Ratios of GMTs and GMFRs of Hemagglutination Inhibition (HAI) Antibodies', 'timeFrame': 'Day 29', 'description': 'The ratio of post-dose HAI antibody GMTs and GMFRs in the IIV group and the MEDI7510 plus IIV group was provided by strain and by cohort for Cohorts 2 and 3 to check the effect of MEDI7510 on IIV when administered together. Humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed on Day 29 by each strain (H1N1, H3N2, B/Yamagata).'}, {'measure': 'Geometric Mean Counts of Cellular Immune Response Against RSV by Respiratory Syncytial Virus Fusion Protein (RSV F) Interferon Gamma (IFNγ) Enzyme-linked Immunosorbent Spot (ELISPOT) Assay', 'timeFrame': 'Baseline (Day 1) and Day 8', 'description': 'The Geometric Mean Counts assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.'}, {'measure': 'GMFRs of Cellular Immune Response Against RSV by RSV F IFNγ ELISPOT Assay', 'timeFrame': 'Day 8', 'description': 'The GMFRs assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples'}, {'measure': 'Percentage of Participants With Post-dose Cell-mediated Immune Response to RSV F by RSV F Peptide Pool IFNγ ELISPOT', 'timeFrame': 'Day 8', 'description': 'Seroresponse defined as a greater than or equal to (\\>=) 3-fold rise from baseline. The Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['RSV', 'Older adults', 'MEDI7510', 'Vaccine'], 'conditions': ['Respiratory Syncytial Virus (RSV)']}, 'referencesModule': {'references': [{'pmid': '36542692', 'type': 'DERIVED', 'citation': 'Chang LA, Phung E, Crank MC, Morabito KM, Villafana T, Dubovsky F, Falloon J, Esser MT, Lin BC, Chen GL, Graham BS, Ruckwardt TJ. A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine. Sci Transl Med. 2022 Dec 21;14(676):eade0424. doi: 10.1126/scitranslmed.ade0424. Epub 2022 Dec 21.'}, {'pmid': '28679495', 'type': 'DERIVED', 'citation': 'Falloon J, Talbot HK, Curtis C, Ervin J, Krieger D, Dubovsky F, Takas T, Yu J, Yu L, Lambert SL, Villafana T, Esser MT. Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses. Clin Vaccine Immunol. 2017 Sep 5;24(9):e00157-17. doi: 10.1128/CVI.00157-17. Print 2017 Sep.'}]}, 'descriptionModule': {'briefSummary': 'The goal of this study is to evaluate the safety, tolerability and immunogenicity of ascending doses of adjuvant in combination with a single dosage level of RSV sF in adults 60 years or older who are healthy or who have stable, chronic underlying medical conditions. This study will also provide preliminary safety and immunogenicity data to support concurrent dosing of MEDI7510 with influenza vaccine (IIV), and to assess the safety of MEDI7510 at a dose previously assessed in the Phase 1a study.', 'detailedDescription': 'A Phase 1b, double-blind, randomized, controlled cohort escalation study evaluating the safety, tolerability and immunogenicity of MEDI7510.\n\nApproximately 264 subjects will be enrolled at approximately 5 study centers in the US and randomized by cohort (Cohort 1 \\[4:1\\]; Cohorts 2 and 3 \\[8:8:3\\]; Cohort 4 \\[5:1\\]) to receive a single intramuscular dose of 1 study vaccine (Cohorts 1 and 4) or a single intramuscular dose of each of 2 study vaccines (Cohorts 2 and 3) administered in contralateral arms.\n\nCohort 1: MEDI7510 formulation (n = 40) or IIV (n = 10) Cohort 2: MEDI7510 formulation and placebo (n = 40) or MEDI7510 formulation and IIV (n = 40) or placebo and IIV (n = 15) Cohort 3: MEDI7510 formulation and placebo (n = 40) or MEDI7510 formulation and IIV (n = 40) or placebo and IIV (n = 15) Cohort 4: MEDI7510 formulation (n = 20) or IIV (n = 4)'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '99 Years', 'minimumAge': '60 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Age greater than or equal to 60 years\n* Ambulatory or ambulatory with assistance (not institutionalized, bedridden, or homebound)\n* Weight greater than 90 lbs\n* Hemoglobin greater than or equal to 10.5 g/dL for women and greater than or equal to 11 g/dL for men\n* Subject able to complete follow-up period of 360 days after dosing\n\nExclusion Criteria:\n\n* History of allergy to: any component of the vaccine; IIV or intolerance of IIV; eggs in adulthood\n* Receipt of seasonal flu shot within 60 days prior to dosing\n* Any unstable acute or chronic medical condition, including one that has resulted in change in therapy (medication or other) in the 30 days prior to randomization or hospitalization in the previous year or might be predicted to result in hospitalization in the year after enrollment. Subjects with severe, untreated or uncontrolled underlying medical disease that might either compromise subject safety or affect the ability to assess safety of the investigational product are excluded. Medications taken on an as-needed basis are permitted to start or stop during the 30 days prior to randomization unless they are medications not previously taken by the subject\n* Clinically significant abnormalities in screening laboratory assessments or screening ECG\n* History of hepatitis B or hepatitis C infection\n* History of Guillain-Barré syndrome\n* Cognitive disorder such that informed consent cannot be obtained directly from the subject\n* Previous vaccination against RSV\n* History of or current autoimmune disorder\n* Immunosuppression caused by disease, including human immunodeficiency virus (HIV) infection, or medications. Any oral prednisone dosing within 30 days of enrollment or planned dosing within the 360-day follow-up period would disqualify. Expected need for immunosuppressive medications during the 360-day follow-up period would disqualify\n* History of splenectomy or of condition affecting splenic function (eg, hemoglobinopathy)\n* History of cancer within preceding 5 years other than treated non-melanoma skin cancer\n* Body Mass Index 40 or higher\n* Receipt of any nonstudy vaccine within 30 days prior to study dosing or expected receipt of nonstudy vaccine within 30 days after study dosing\n* Receipt of any investigational product in the 90 days prior to randomization or expected receipt of investigational product during the period of study follow-up\n* Receipt of immunoglobulins or blood products within 4 months of study dosing (120 days) or expected receipt of investigational product during the period of study follow-up\n* Current bleeding or clotting disorder including use of anticoagulants other than drugs with anti-platelet activity (such as nonsteroidal anti-inflammatory drugs, clopidogrel, ticagrelor or aspirin)\n* Expected receipt of antipyretic or analgesic medication on a daily or every other day basis from randomization through 72 hours after receipt of IP (Note: A daily dose of aspirin is not considered a contraindication to enrollment.)\n* Subjects who have significant scarring, tattoos, abrasions, cuts, or infections over the deltoid region of both arms that, in the investigators opinion, could interfere with evaluation of injection site local reactions\n* Concurrent enrollment in another clinical study that involves any invasive clinical procedure, including phlebotomy\n* History of alcohol or drug abuse or psychiatric disorder that, in the investigators opinion, would affect the subject's safety or compliance with study\n* Employees of individuals directly involved with the conduct of the study, individuals who themselves are involved with the conduct of the study, or immediate family members of such individuals"}, 'identificationModule': {'nctId': 'NCT02289820', 'briefTitle': 'A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults', 'organization': {'class': 'INDUSTRY', 'fullName': 'MedImmune LLC'}, 'officialTitle': 'A Phase 1b Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults', 'orgStudyIdInfo': {'id': 'D4420C00004'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'description': 'Participants will receive a single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.', 'interventionNames': ['Biological: MEDI7510']}, {'type': 'EXPERIMENTAL', 'label': 'MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2', 'description': 'Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.', 'interventionNames': ['Biological: MEDI7510', 'Biological: IIV']}, {'type': 'EXPERIMENTAL', 'label': 'MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3', 'description': 'Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.', 'interventionNames': ['Biological: MEDI7510']}, {'type': 'EXPERIMENTAL', 'label': 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4', 'description': 'Participants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.', 'interventionNames': ['Biological: MEDI7510']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Inactivated Influenza Vaccine (IIV)', 'description': 'Participants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.', 'interventionNames': ['Biological: IIV']}], 'interventions': [{'name': 'MEDI7510', 'type': 'BIOLOGICAL', 'description': 'RSV sF antigen plus adjuvant', 'armGroupLabels': ['MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1', 'MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2', 'MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3', 'MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4']}, {'name': 'IIV', 'type': 'BIOLOGICAL', 'description': 'Marketed Inactivated Influenza Vaccine', 'armGroupLabels': ['Inactivated Influenza Vaccine (IIV)', 'MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'city': 'South Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 25.7076, 'lon': -80.29338}}, {'city': 'Kansas City', 'state': 'Missouri', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 39.09973, 'lon': -94.57857}}, {'city': 'Raleigh', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}], 'overallOfficials': [{'name': 'Judith Falloon, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'MedImmune LLC'}, {'name': 'Eric Sheldon, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Miami Research Associates'}, {'name': 'Craig Curtis, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Compass Research'}, {'name': 'John Ervin, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'The Center for Pharmaceutical Research'}, {'name': 'Wayne Harper, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Wake Research Associates'}, {'name': 'H. Keipp Talbot, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Vanderbilt University Medical Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'MedImmune LLC', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}